Please login to the form below
migraine
This page shows the latest migraine news and features for those working in and with pharma, biotech and healthcare.
Lundbeck drops Parkinson’s drug acquired in €905m deal
It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from
Latest news
-
Biohaven gets FDA approval for migraine drug Nurtec ODT
Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T. ... it offers patients a chance at freedom from migraine pain and their most bothersome symptom…at two hours”.
-
Modest meeting sees only two drugs recommended by CHMP
Lilly’s migraine med Emgality receives negative opinion for label extension. The European Medicines Agency’s advisory Committee for Medicinal Products for Human Use has recommended only one new drug and ... one generic medicine at its latest meeting,
-
Lundbeck gets US approval for migraine drug at heart of Alder takeover
US regulator clears CGRP inhibitor under Vyepti trade name. Lundbeck has the payoff it was looking for from its acquisition of Alder Biopharma last year, claiming FDA approval for migraine prevention ... specialists aren’t rushing to switch wholesale
-
Teva’s weak pipeline hit by Tourette’s drug trial failure
It’s one of a clutch of new drugs – that also includes migraine prevention therapy Ajovy (fremanezumab) – that Teva needs to perform well and help it recover from the double whammy
-
Botox strength bolsters Allergan ahead of AbbVie takeover
The sales growth comes despite tougher competition in the market from new migraine drugs as well as rivals like Dysport in its medical aesthetics indications. ... Allergan chief executive Brent Saunders said Allergan is entering 2020 with “strong
More from news
Approximately 26 fully matching, plus 148 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
Eli Lilly/Dong Pharmaceuticals’ 5-HT1f agonist Reyvow was approved in the US in October 2019 as the first acute treatment for migraine in 20 years. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved for acute migraine, which
-
20 for 2020 – Five pharma companies to watch
pipeline. He argues, however, that layering in products like Allergan’s blockbuster wrinkle and migraine treatment Botox will improve near-term cashflow and help fund the roll-out of a new ... year. Botox is facing tougher competition in the market
-
Key considerations for disease- modifying Parkinson’s disease trials
Published adherence in migraine-prophylaxis (as a comparable indication) indicates 92.6% adherent at one month, 40.7% at two months, 30.9% at three months, 24.8% at four months,
-
Deal Watch January 2018
Teva’s CGRP patent portfolio to develop, manufacture and commercialise eptinezumab, its phase III CGRP antibody for the treatment of migraine. In exchange for the licence, Alder will withdraw its appeal
-
The good, the bad and the ugly
Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.
More from intelligence
Approximately 1 fully matching, plus 25 partially matching documents found.
Latest appointments
-
Newron Pharma appoints commercial affairs VP
He brings sales and marketing experience from Johnson &Johnson, and served as franchise marketing director for psychiatry, Parkinson's disease and migraine products at Novartis.
-
Red Door Unlimited appoints new digital strategy head
Prior to joining the agency, Morgan worked on accounts in patient advocacy for cancer immunotherapy, hepatitis C treatments and migraines for Firstlight PR and Hill and Knowlton Strategies.
-
Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer
operations. This includes ensuring the success of current products, such as Sumavel DosePro for migraine, as well as soon to be launched products, such as Zohydro, which is pending FDA approval
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Infographic
Migraine market snapshot. Research Partnership’s migraine market snapshot offers an introduction to the real world patient data collected by their Therapy Watch migraine study.
-
Research Partnership has published a new Living with Chronic Pain market report for 2016
Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients with diabetic neuropathic pain, chronic lower back pain, cancer pain and headache/migraine pain.
-
What it takes to win at Cannes Health Lions
As for Martin, DDB Remedy won a Silver and Two bronze awards for an integrated campaign for Excedrin, an OTC migraine treatment in the US, helping to address the issue that ... people often respond to someone with a migraine by just saying that it’s
-
Double Communiqué award win for 90TEN
The Migraine Unlocked campaign took a surround-sound communications approach using advertising, media and grassroots campaigning to maximise exposure to sufferers and their loved ones. ... Commenting on Migraine Unlocked, t he Comm uniqué judges said:
-
90TEN nominated for five Communique Awards including Small Consultancy of the Year
The Allergan “Migraine Unlocked” campaign is a finalist in Excellence in Communications via a Live Event or Stand-Alone Activity, and an HCV programme for AbbVie has been recognised in the
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November
- UK scientists begin testing BCG vaccine for severe COVID-19 protection
- Send Us a Message
- The Truth about Doctors
- Eli Lilly’s COVID-19 antibody trial paused due to safety issue
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- WHO trial casts doubt on remdesivir's efficacy
- Galapagos mid-stage trial failure raises concerns for Gilead deal
- How Far Do You Want To Go?
- Every superhero has an origin story – what’s yours?
- Live Webinar: Solving the Caregiver Crisis Through Technology
PMHub
Viseven
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...
Latest intelligence
- How Far Do You Want To Go?
- Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
- "Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
- Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
- Whats the difference between patient engagement and patient experience?
- We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....
Quick links
Infographics
